Severe hypogammaglobulinemia persisting for 6 years after treatment with rituximab combined chemotherapy due to arrest of B lymphocyte differentiation together with alteration of T lymphocyte homeostasis

International Journal of Hematology

Volumn 91, Issue 3, 2010, Pages 501-508

  Irie, Erika ^a   Shirota, Yuko ^a   Suzuki, Chihiro ^a   Tajima, Yumi ^a   Ishizawa, Kenichi ^a   Kameoka, Junichi ^a   Harigae, Hideo ^a   Ishii, Tomonori ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Hypogammaglobulinemia; Lymphoma class switch; Rituximab

Indexed keywords

ACICLOVIR; B CELL ACTIVATING FACTOR; BLEOMYCIN; CD27 ANTIGEN; CD45RA ANTIGEN; CD69 ANTIGEN; CHEMOKINE RECEPTOR CCR7; CYCLOPHOSPHAMIDE; FAS ANTIGEN; HLA DR ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 10; INTERLEUKIN 15; INTERLEUKIN 6; PIRARUBICIN; PREDNISOLONE; PROCARBAZINE; RITUXIMAB; TRANSCRIPTION FACTOR FOXP3; VINCRISTINE;

ADULT; APOPTOSIS; ARTICLE; B LYMPHOCYTE DIFFERENTIATION; BONE MARROW SUPPRESSION; CANCER REGRESSION; CASE REPORT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL LINEAGE; CONTROLLED STUDY; DRUG DOSE REDUCTION; FEMALE; FOLLICULAR LYMPHOMA; HERPES ZOSTER; HUMAN; IMMUNOGLOBULIN DEFICIENCY; IMMUNOGLOBULIN PRODUCTION; MEMORY CELL; MEMORY T LYMPHOCYTE; MULTIPLE CYCLE TREATMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPIC VARIATION; PLASMA CELL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE;

AGAMMAGLOBULINEMIA; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; B-LYMPHOCYTES; BLEOMYCIN; CELL DIFFERENTIATION; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HOMEOSTASIS; HUMANS; IMMUNOPHENOTYPING; LYMPHOMA, FOLLICULAR; MIDDLE AGED; PREDNISONE; PROCARBAZINE; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTES; VINCRISTINE;

EID: 77950917503     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-010-0528-6     Document Type: Article

References (15)

1. P McLaughlin, et al. 1998 Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program J Clin Oncol 16 2825 2833 1:CAS:528: DyaK1cXlsFCgu7c%3D 9704735 (Pubitemid 28363048)
2. DG Maloney, et al. 1997 IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma J Clin Oncol 15 3266 3274 1:CAS:528:DyaK2sXmslOlu7g%3D 9336364 (Pubitemid 27419340)
3. J Shortt A Spencer 2006 Adjuvant rituximab causes prolonged hypogammaglobulinaemia following autologous stem cell transplant for non-Hodgkin's lymphoma Bone Marrow Transplant 38 433 436 10.1038/sj.bmt.1705463 1:CAS:528:DC%2BD28XovF2ksL8%3D 16892074 (Pubitemid 44340374)
4. A Shimoni, et al. 2003 Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma Br J Haematol 122 457 464 10.1046/j.1365-2141.2003.04446. x 1:CAS:528:DC%2BD3sXmvFyns7k%3D 12877674 (Pubitemid 36951631)
5. SM Horwitz, et al. 2004 Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma Blood 103 777 783 10.1182/blood-2003-04-1257 1:CAS:528: DC%2BD2cXhtValtbY%3D 12907446 (Pubitemid 38129532)
6. S Imashuku, et al. 2004 Prolonged hypogammaglobulinemia following rituximab treatment for post transplant Epstein-Barr virus-associated lymphoproliferative disease Bone Marrow Transplant 33 129 130 10.1038/sj.bmt.1704307 1:STN:280:DC%2BD2c%2FgslWjsQ%3D%3D 14647260 (Pubitemid 38159719)
7. M Nishio, et al. 2006 Hypogammaglobulinemia with a selective delayed recovery in memory B cells and an impaired isotype expression after rituximab administration as an adjuvant to autologous stem cell transplantation for non-Hodgkin lymphoma Eur J Haematol 77 226 232 10.1111/j.1600-0609.2006.00693.x 1:CAS:528:DC%2BD28XhtVSku7jE 16923109 (Pubitemid 44181385)
8. SA Miles M McGratten 2005 Persistent panhypogammaglobulinemia after CHOP-rituximab for HIV-related lymphoma J Clin Oncol 23 247 248 10.1200/JCO.2005.05.282 15625386 (Pubitemid 41702649)
9. AR Walker, et al. 2008 Profound hypogammaglobulinemia 7 years after treatment for indolent lymphoma Cancer Invest 26 431 433 10.1080/ 07357900701809068 18443965 (Pubitemid 351601392)
10. M Nishio, et al. 2007 Delayed redistribution of CD27, CD40 and CD80 positive B cells and the impaired in vitro immunoglobulin production in patients with non-Hodgkin lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation Br J Haematol 137 349 354 10.1111/j.1365-2141.2007.06584.x 1:CAS:528:DC%2BD2sXntVSntbw%3D 17456057 (Pubitemid 46650258)
11. M Nishio, et al. 2009 FCGR3A-158V/F polymorphism may correlate with the levels of immunoglobulin in patients with non-Hodgkin's lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation Eur J Haematol 82 143 147 10.1111/j.1600-0609.2008.01174.x 1:CAS:528:DC%2BD1MXisVKhurk%3D 19018870
12. A Saxon, et al. 1995 B cells from a distinct subset of patients with common variable immunodeficiency (CVID) have increased CD95 (Apo-1/fas), diminished CD38 expression, and undergo enhanced apoptosis Clin Exp Immunol 102 17 25 1:STN:280:DyaK28%2Fgtl2ntw%3D%3D 7554385
13. JS Jaffe W Strober MC Sneller 1993 Functional abnormalities of CD8+ T cells define a unique subset of patients with common variable immunodeficiency Blood 82 192 201 1:STN:280:DyaK3szhtlWqtA%3D%3D 8100719 (Pubitemid 23188764)
14. JJ Wright, et al. 1990 Characterization of common variable immunodeficiency: identification of a subset of patients with distinctive immunophenotypic and clinical features Blood 76 2046 2051 1:STN:280: DyaK3M%2FlsFWjtw%3D%3D 2146980
15. E Baumert, et al. 1992 Immunophenotypical alterations in a subset of patients with common variable immunodeficiency (CVID) Clin Exp Immunol 90 25 30 1:STN:280:DyaK3s%2FgvFSrtQ%3D%3D 1395097